RAPT Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RAPT and other ETFs, options, and stocks.

About RAPT

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA. 

CEO
Brian Russell Wong
CEOBrian Russell Wong
Employees
68
Employees68
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2015
Founded2015
Employees
68
Employees68

RAPT Key Statistics

Market cap
961.71M
Market cap961.71M
Price-Earnings ratio
-3.08
Price-Earnings ratio-3.08
Dividend yield
Dividend yield
Average volume
300.34K
Average volume300.34K
High today
$34.98
High today$34.98
Low today
$33.96
Low today$33.96
Open price
$34.05
Open price$34.05
Volume
11.01K
Volume11.01K
52 Week high
$42.39
52 Week high$42.39
52 Week low
$5.67
52 Week low$5.67

Stock Snapshot

As of today, RAPT Therapeutics(RAPT) shares are valued at $34.71. The company's market cap stands at 961.71M, with a P/E ratio of -3.08.

During the trading session on 2026-01-14, RAPT Therapeutics(RAPT) shares reached a daily high of $34.98 and a low of $33.96. At a current price of $34.71, the stock is +2.2% higher than the low and still -0.8% under the high.

Trading activity shows a volume of 11.01K, compared to an average daily volume of 300.34K.

The stock's 52-week range extends from a low of $5.67 to a high of $42.39.

The stock's 52-week range extends from a low of $5.67 to a high of $42.39.

RAPT News

TipRanks 2h
RAPT Therapeutics Showcases Ozureprubart Progress, Strengthened Outlook

Claim 70% Off TipRanks Premium RAPT Therapeutics ( (RAPT) ) has provided an announcement. On January 14, 2026, RAPT Therapeutics presented at the 44th Annual...

TipRanks 5d
RAPT Therapeutics: De-Risked ‘Bio-Better’ Ozureprubart Underpins Buy Rating and Upside to Target Price

RAPT Therapeutics (RAPT) has received a new Buy rating, initiated by Piper Sandler analyst, Yasmeen Rahimi. Claim 70% Off TipRanks Premium Unlock hedge fund-lev...

Analyst ratings

92%

of 12 ratings
Buy
91.7%
Hold
8.3%
Sell
0%

People also own

Based on the portfolios of people who own RAPT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .